GRIFOLS (GRFS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$8.6B

Revenue (quarter)

$2.1B

Revenue growth (year over year)

−3.87%

Gross profit (trailing twelve months)

$3.2B

Gross margin

36.97%

Net income (trailing twelve months)

$624.3M

Net income (quarter)

$208.9M

Net income growth (year over year)

+27.71%

Net margin

7.27%

Return on equity

8.42%

EPS (trailing twelve months)

$0.76

Book value per share

$9.21

P/E (trailing twelve months)

9.52

Price to book

0.55

Debt to assets

60.28%

Payout ratio

25.27%

Dividend yield

1.06%

Company profile

Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.

• Is GRIFOLS (GRFS) profitable?

  Yes. GRIFOLS earned $624.3M in net income over the trailing twelve months, a net margin of 7.27%.

• How much revenue does GRIFOLS (GRFS) make?

  GRIFOLS generated $8.6B in revenue over the trailing twelve months, down 3.87% year over year.

• What is GRFS's P/E ratio?

  GRIFOLS trades at 9.5 times trailing twelve-month earnings, on an EPS of $0.76.

• How do I buy stock in GRIFOLS (GRFS)?

  GRFS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.